Safe Harbor Statement: Statements in this press release that are not purely historical, including statements regarding Peregrine Pharmaceuticals intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements under the Private Securities Litigation Reform Act of 1995 www.erectalis.net/pharmacology.html . The forward-looking statements involve risks and including, but not including, but not limited to, limits the risk. This Bavituximab safety profile in a combination therapy trial will not have the same level of security as in the Phase Ia trial, the risk that the results of future studies are not Ia in the results of the study phase, fundingate the risk was found that Bavituximab will not be well tolerated in increasing doses or show promising results in other viral indications and the risk that results from human trials with Bavituximab not plus radiation or chemotherapy correlate to the results of preclinical studies. It is important to note that the company’s actual results to differ materially from those in such forward in such forward looking statements. Among the factors that could differ which could cause actual results include, but are not limited to, uncertainties associated with completion of the preclinical and clinical trials for our technologies of third parties, the early phase of product development, the significant cost of our products, like all to develop our products currently in development, preclinical studies or clinical trials, and obtaining additional funding factors, including thee development of our products support; obtaining regulatory approval for our technologies; winning anticipated timing of regulatory filings and the potential success of approval and comply with government rules in our business. Our business could be a number of other factors, including the risk factors listed from time to time in our SEC reports to be affected, but not limited to, the Annual Report 30 Report on Form 10-K for the year ended April 2006. The company cautions investors not to rely too heavily on the forward-looking statements in this news release. Peregrine Pharmaceuticals assumes no obligation and disclaims any obligation to update or revise forward-looking statements in this press release.
GCP guidelines.tical company with a portfolio of innovative, clinical stage for the treatment of hepatitis C virus infection and cancer: – Initiate Peregrine Pharmaceuticals Peregrine To Bavituximab Combination Therapy study in India with several cancer chemotherapy , announced today that it plans to to initiate a clinical trial completed in India Bavituximab in combination with chemotherapy. The study is designed primarily to evaluate the safety and tolerability of Bavituximab with several standard chemotherapy often to test for treatment of major cancers, including breast, lung and pancreatic cancer. The company has an experienced Indian contract research organization with recent success in managing a registration clinical trial for a new therapeutic monoclonal antibodies together. The new cancer trial will be conducted according to internationally accepted ICH GCP guidelines. Peregrine expects that the results from this study, together with data from the ongoing U.S. Phase I cancer study, and Eli Lilly, the Bavituximab above in Phase II cancer trials in 2007. Preclinical studies have repeatedly demonstrated the exciting potential Bavituximab plus chemotherapy for the treatment of solid tumors, said Steven W. President and CEO of Peregrine. This new study complements our ongoing Phase l cancer trial in the U.S. Is an important milestone allows us to accelerate the clinical evaluation of Bavituximab anti-cancer potential. Mr. King continued, have led in recent years global pharmaceutical companies such as Pfizer, GlaxoSmithKline, Roche and Eli Lilly, a growing number of large clinical trials in India, taking advantage of the country’s world-class clinical research facilities that leverage India’s large cadre of Western – trained medical personnel and enormous pool of patients like in clinical trials to participate. We look forward to the cooperation with our Indian employees the Bavituximab cancer program that we believe has considerable potential for patients promoting. In the United StatesBavituximab is currently being studied in Phase I clinical trials in the U.S. For the treatment of solid tumors and chronic hepatitis C infection Clinical has collected data shown so far that has Bavituximab safe and well tolerated, and it has plenty of. Encouraging signs of anti-viral activity in hepatitis C study reported. This new multi-center cancer trial is a pilot safety and pharmacokinetic study in patients scheduled Bavituximab with docetaxel, gemcitabine or carboplatin / paclitaxel for eight weeks. Current chemotherapies are part of the current standard of care for a number of solid tumor types such as breast, lung and pancreatic cancer. Endpoints include safety and drug pharmacokinetics and patients for tumor response according to response Time evaluation Criteria in Solid tumors criteria are evaluated. Peregrine has completed an investigator meeting in India to prepare for trial initiation, and the study has already been cleared to go to one of three sites. Clearance from the other sites is on schedule and is expected soon. Continue reading